2021 Quota and Comp

Discussion in 'Bioventus' started by anonymous, Oct 9, 2020 at 8:59 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

     

  2. anonymous

    anonymous Guest

    they or their staff just have to enter it as an order in their emr system. pretty simple. cast tech/ MA will just have a pt responsibility form for the pt to sign just like when a cam walker boot or brace is dispensed. They will stock dozens of the generic stims in their dme rooms, more if it's a big ortho clinic. These dme groups know how to make profits, trust me.

    By the way, do we know the names of the new units coming out?
     
  3. anonymous

    anonymous Guest

    Of course JN and DV are in a relationship. It was disclosed with HR years ago so what’s the big deal?
     
  4. anonymous

    anonymous Guest

    Not to throw fuel on the fire but I’m still waiting for our company to address the new OA competitors coming this q1. Crickets. So, here will be the platform. Organogenesis just received fda approval for an amniotic injection specifically for the reduction in pain and improved range of motion due to mild to moderate OA. The product is considered a liquid allograft offering higher reimbursement to the physician. Why do we keep falling behind curve and end up chasing market changes and trends? If we are going to be the OA leader, why can’t we seem to lead? We only chase.
     
  5. anonymous

    anonymous Guest

    Not to throw fuel on the fire but I’m still waiting for our company to address the new OA competitors coming this q1. Crickets. So, here will be the platform. Organogenesis just received fda approval for an amniotic injection specifically for the reduction in pain and improved range of motion due to mild to moderate OA. The product is considered a liquid allograft offering higher reimbursement to the physician. Why do we keep falling behind curve and end up chasing market changes and trends? If we are going to be the OA leader, why can’t we seem to lead? We only chase.
     
  6. anonymous

    anonymous Guest

    Motys isn’t even in the chase it will be more than a year before a safety study is published.
     
  7. anonymous

    anonymous Guest

     
  8. anonymous

    anonymous Guest

    I don't see organogenesis and Renu making that big of a wave. It requires cryopreservation which is going to be a cost barrier for a lot of customers.
     
  9. anonymous

    anonymous Guest

    Not as much of a barrier as motys being half a decade behind the gate
     
  10. anonymous

    anonymous Guest

    They can overnight product on dry ice for patients. They also have a freezer program for clinics. Organogenesis has their stuff together. And yes.....BV is running behind as always. "Global Leader in orthobiologics" is comical.
     
  11. anonymous

    anonymous Guest

    How will the IPO filing this week affect business?
     
  12. anonymous

    anonymous Guest

    You are about to see a mass exodus from this place. It will show you how self serving most who have hung around here have been for quite some time. It’s always been about the “hope” of an IPO they could cash in on particularly those VP and higher who have shares. They’ve known and continue to know this ship has been on a slow decline for years due to horrible short sighted leadership with only one goal which is about to happen. Meanwhile we all get stuck with their horrible decisions and leadership that wouldn’t last 1 week with any other company.
     
  13. anonymous

    anonymous Guest

    Just came on this board to see how the tenor was. So thankful I left that shitshow. I went back to pharma- for all the snide remarks I caught when at BV for having a background in pharma, just know I’m now working half as hard for twice the money as I did at BV. I don’t have to do anything that’s unethical to make my goals. My company provides me everything I need to do my job. No patients call me on evenings, weekends, or vacation time. It would all be worth it if BV were paying for that kind of work, but folks, they just aren’t!
     
  14. anonymous

    anonymous Guest

     
  15. anonymous

    anonymous Guest

     
  16. anonymous

    anonymous Guest

    Like most things on here the haters were wrong about the sinking ship. IPO!!!!!
     
  17. anonymous

    anonymous Guest

    An IPO is exciting but doesn’t mean a company is going to be successful
     
  18. anonymous

    anonymous Guest

    Ha! Don’t celebrate just yet. They couldn’t get it off the ground back in 2016...
     
  19. anonymous

    anonymous Guest

    The goal of this company as long as I have been here has been to get a IPO. It shows in all we do. A series of short sighted moves that lack any real business strategy beyond getting to a IPO. They wanted to do this a couple years ago, but all hopes were destroyed by the rampant compliance violations. Now those are swept under the rug so no one sees them. My question is what will the business do once it’s sole purpose for existence is achieved? Like the earlier post, I believe people will start leaving here in rapid fashion primarily because taking this company public is going to expose a lot of skeletons, horrible decisions, and many people in positions that shouldn’t be. DV will be the first and I have my popcorn ready.
     
  20. anonymous

    anonymous Guest

    Swept under the rug? Were you not on last week's call? Sounded like it was anything but swept under the rug.
     
  21. anonymous

    anonymous Guest

    What will change, if the IPO is successfully launched, is now they report to Wall Street. Earnings are all that will matter. When driving earnings, the first thing you drop is payroll.